Imprimis Pharma (IMMY) Misses Q1 EPS by 16c

Imprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of ($0.43), $0.16 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $3.24 million.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Canterbury Park (CPHC) Misses Q2 EPS by 3c
• Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c